m 6 A mRNA methylation by METTL14 regulates early pancreatic cell differentiation.

N ⁶ -methyladenosine (m ⁶ A) is the most abundant chemical modification in mRNA and plays important roles in human and mouse embryonic stem cell pluripotency, maintenance, and differentiation. We have recently reported that m ⁶ A is involved in the postnatal control of β-cell function in physiological states and in type 1 and 2 diabetes. However, the precise mechanisms by which m ⁶ A acts to regulate the development of human and mouse pancreas are unexplored. Here, we show that the m ⁶ A landscape is dynamic during human pancreas development, and that METTL14, one of the m ⁶ A writer complex proteins, is essential for the early differentiation of both human and mouse pancreatic cells.
Competing Interests: Disclosure and competing interests statement SK is an employee of Boehringer Ingelheim Pharmaceuticals, Inc. RNK is on the Scientific Advisory Board of Novo Nordisk, Biomea and Inversago Therapeutics. CH is a scientific founder, a member of the scientific advisory board and equity holder of Aferna Bio, Inc. and AccuaDX Inc., a scientific co-founder and equity holder of Accent Therapeutics, Inc., and a member of the scientific advisory board of Rona Therapeutics. RIG is a co-founder, scientific advisory board member, and equity holder of Redona Therapeutics. The Gregory lab receives or has received research funding from Sanofi, Astellas, and Ono. The authors declare no competing interests.
(© 2024. The Author(s).)